On the 7th, Yuhan Corporation announced that it received a notice of technology return for the new drug candidate 'BI3006337(YH25724)' that it had exported to the global pharmaceutical company Boehringer Ingelheim.
BI3006337 is a dual-action antibody drug targeting glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) that Yuhan Corporation transferred to Boehringer Ingelheim in July 2019.
The two companies entered into a joint development and licensing agreement at that time to develop the drug as a treatment for metabolic-associated steatotic liver disease (MASH) and related liver diseases. GLP-1 is a human hormone that promotes insulin secretion. THR-β is involved in insulin secretion, and FGF21 lowers blood sugar and triglycerides while increasing energy metabolism, fat utilization, and lipid excretion.
Yuhan Corporation noted that it is considering self-developing the returned substance. A representative of Yuhan Corporation stated, "There is no financial loss as there is no obligation to return the $40 million contract fee received from the technology transfer and the $10 million milestone fee (stage-specific technology fee)."